Akums Drugs

48
Sell
  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE09XN01023
  • NSEID: AKUMS
  • BSEID: 544222
INR
500.00
3.2 (0.64%)
BSENSE

Apr 02

BSE+NSE Vol: 1.79 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Consolidated - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
No of Months
12
12
12
12
12
12
Operating Income
4,118.00
4,178.00
3,654.00
3,671.00
2,722.00
2,414.00
Less :Inter divisional transfers
0.00
0.00
0.00
0.00
0.00
0.00
Less: Excise
0.00
0.00
0.00
0.00
0.00
0.00
Net Sales
4,118.00
4,178.00
3,654.00
3,671.00
2,722.00
2,414.00
Expenditure (Ex Depriciation)
Stock Adjustments
-1.00
12.00
24.00
-87.00
-30.00
-28.00
Raw Materials Consumed
2,435.00
2,537.00
2,249.00
2,432.00
1,721.00
1,502.00
Power & Fuel Cost
164.00
160.00
147.00
110.00
76.00
82.00
Employee Cost
715.00
646.00
590.00
507.00
420.00
438.00
Operating Expenses
98.00
102.00
108.00
104.00
81.00
66.00
General and Administration Expenses
-1.00
-1.00
-1.00
-1.00
-1.00
-1.00
Selling and Distribution Expenses
55.00
55.00
54.00
51.00
23.00
25.00
Cost of Software developments
0.00
0.00
0.00
0.00
0.00
0.00
Miscellaneous Expenses
83.00
434.00
76.00
568.00
139.00
95.00
Expenses Capitalised
0.00
0.00
0.00
0.00
0.00
0.00
Total Expenditure
3,653.00
4,055.00
3,360.00
3,763.00
2,485.00
2,240.00
Operating Profit (PBDIT) excl Other Income
464.00
122.00
293.00
-91.00
237.00
174.00
Other Income
52.00
34.00
90.00
22.00
21.00
27.00
Operating Profit (PBDIT)
516.00
157.00
384.00
-69.00
258.00
201.00
Interest
34.00
50.00
46.00
16.00
6.00
19.00
Profit before Depriciation and Tax
482.00
106.00
337.00
-85.00
251.00
181.00
Depreciation
153.00
125.00
112.00
94.00
69.00
66.00
Profit Before Taxation & Exceptional Items
328.00
-19.00
225.00
-180.00
181.00
114.00
Exceptional Income / Expenses
0.00
0.00
0.00
0.00
0.00
0.00
Profit Before Tax
345.00
-45.00
150.00
-193.00
172.00
113.00
Provision for Tax
1.00
-46.00
52.00
57.00
48.00
70.00
Profit After Tax
343.00
0.00
98.00
-251.00
123.00
43.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
Adj to Profit After Tax
0.00
0.00
0.00
0.00
0.00
0.00
Profit Balance B/F
630.00
638.00
557.00
832.00
770.00
836.00
Profit Available for appropriations
969.00
634.00
652.00
579.00
894.00
880.00
Appropriations
969.00
634.00
652.00
579.00
894.00
880.00
Equity Dividend (%)
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Earnings Per Share
22.60
-0.28
6.63
-17.65
949.08
357.03
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is -1.44% vs 14.32% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 277.67% vs -58.17% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is -31.64% vs 9.45% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is 43,416.08% vs -99.19% in Mar 2024

Compare Profit and Loss Results of Akums Drugs
Markets Mojo
Figures in Cr
consolidated - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
4,118.00
2,013.00
2,105.00
104.57%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
4,118.00
2,013.00
2,105.00
104.57%
Expenditure (Ex Depriciation)
Stock Adjustments
-1.00
60.00
-61.00
-101.67%
Raw Materials Consumed
2,435.00
919.00
1,516.00
164.96%
Power & Fuel Cost
164.00
11.00
153.00
1,390.91%
Employee Cost
715.00
240.00
475.00
197.92%
Operating Expenses
98.00
34.00
64.00
188.24%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
55.00
105.00
-50.00
-47.62%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
83.00
45.00
38.00
84.44%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
3,653.00
1,522.00
2,131.00
140.01%
Operating Profit (PBDIT) excl Other Income
464.00
490.00
-26.00
-5.31%
Other Income
52.00
16.00
36.00
225.00%
Operating Profit (PBDIT)
516.00
507.00
9.00
1.78%
Interest
34.00
1.00
33.00
3,300.00%
Profit before Depriciation and Tax
482.00
505.00
-23.00
-4.55%
Depreciation
153.00
36.00
117.00
325.00%
Profit Before Taxation & Exceptional Items
328.00
469.00
-141.00
-30.06%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
345.00
431.00
-86.00
-19.95%
Provision for Tax
1.00
117.00
-116.00
-99.15%
Profit After Tax
343.00
313.00
30.00
9.58%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
630.00
601.00
29.00
4.83%
Profit Available for appropriations
969.00
915.00
54.00
5.90%
Appropriations
969.00
915.00
54.00
5.90%
Equity Dividend (%)
0%
1170%
-1,170.00
Earnings Per Share
22.6
179.46
-156.86
-87.41%
Profit And Loss - Net Sales
Net Sales 4,118.16 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is -1.44% vs 14.32% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 464.48 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 277.67% vs -58.17% in Mar 2024

Profit And Loss - Interest
Interest 34.60 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is -31.64% vs 9.45% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 343.78 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 43,416.08% vs -99.19% in Mar 2024